The Mayo Clinic and Washington, D.C.-based Gentag, Inc., have reached an agreement to develop the next generation of wearable biosensors designed to fight obesity and diabetes.
The wearable patch sensors are the size of a small bandage, and are designed to be painless, wireless and disposable. In the bandage is a sensor that communicates via a closed-loop diabetes management system which is compatible with cell phones. The system will allow researchers to monitor movement and develop treatments for obesity and related conditions.
A joint intellectual property (IP) agreement with Mayo Clinic made the research and development of the tool possible. Gentag signed a patent pooling agreement with Mayo Clinic for the management of IP related to wearable patch sensor and wireless communication technologies. Under the agreement, certain patent rights and technologies of both Mayo Clinic and Gentag will be combined and commercialized.
The two firms will collaborate with third parties under license to bring Mayo Clinic's expertise in medicine and clinical practices to the public by the development of the next generation of wearable skin patch technologies from Gentag in the areas of diabetes and obesity management. More than 50 issued patents and technologies are being offered for licensing under the agreement.
In addition, Mayo's Micro-Miniature Transceiver chip will be combined with Gentag's radar-responsive tag technology and integrated under license to create a new type of communication chip that will combine Near Field Communications and Body Area Networks, as well as long-range wireless communication and geolocation.
Register or login for access to this item and much more
All Health Data Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access